BioCardia, Inc. Impairment of Long-Lived Assets Held-for-use
BioCardia, Inc. (BCDA) reported Impairment of Long-Lived Assets Held-for-use of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-29.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfLongLivedAssetsHeldForUse · last filed 2022-03-29
- BioCardia, Inc. impairment of long-lived assets held-for-use for fiscal 2021 was $0.00.
- BioCardia, Inc. impairment of long-lived assets held-for-use for fiscal 2020 was $0.00.
- BioCardia, Inc. impairment of long-lived assets held-for-use for fiscal 2019 was $0.00.
- BioCardia, Inc. impairment of long-lived assets held-for-use for fiscal 2018 was $0.00.
| Period end | Impairment of Long-Lived Assets Held-for-use 12 month |
|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-03-29 |
| 2020-12-31 | $0.00 10-K · filed 2021-03-30 |
| 2019-12-31 | $0.00 10-K · filed 2020-04-09 |
| 2018-12-31 | $0.00 10-K · filed 2019-04-02 |
| 2017-12-31 | $0.00 10-K · filed 2018-03-16 |
| 2016-12-31 | $0.00 10-K · filed 2018-03-16 |
| 2015-12-31 | $0.00 10-K · filed 2018-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |